Patents-Review.com
ClassID:

116520 ⎘

C12Y302/01022 - CPC Classification

Classification description:

Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2); Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1) Alpha-galactosidase (3.2.1.22)

Recent Application in this class:
#1
20260150869
2026-06-04

A METHOD FOR ENHANCING THE FLAVOR AND/OR THE TEXTURE OF A PLANT-BASED PRODUCT

 #2
20260146242
2026-05-28

ALPHA-GALACTOSIDASE PROTEIN FOR ENZYME REPLACEMENT THERAPY (ERT) AND METHODS OF USE

 #3
20260109677
2026-04-23

COMPOUNDS, DEVICES, AND USES THEREOF

 #4
20260049297
2026-02-19

STABILIZED ALPHA-GALACTOSIDASE AND USES THEREOF

 #5
20250263685
2025-08-21

OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF

 #6
20250257105
2025-08-14

ICAM-1 TARGETED FUSION ENZYMES

 #7
20250242057
2025-07-31

Disulfide Bond Stabilized Polypeptide Compositions And Methods Of Use

 #8
20250207118
2025-06-26

HUMAN ALPHA-GALACTOSIDASE VARIANTS

 #9
20250188433
2025-06-12

COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMES

 #10
20250188428
2025-06-12

NOVEL IN VITRO AND IN VIVO ENRICHMENT STRATEGY TARGETING LYMPHOCYTES DERIVED FROM VECTOR TRANSDUCED HSCS FOR THERAPY OF DISORDERS

 #11
20250179460
2025-06-05

HUMAN ALPHA-GALACTOSIDASE VARIANTS

 #12
20250170221
2025-05-29

USE OF LENTIVECTOR-TRANSDUCED T-RAPA CELLS FOR AMELIORATION OF LYSOSOMAL STORAGE DISORDERS

 #13
20250163469
2025-05-22

ADENO-ASSOCIATED VIRUS VARIANT CAPSIDS AND METHODS OF USE THEREOF

 #14
20250161221
2025-05-22

Lyophilized Pharmaceutical Compositions Comprising A Lipid Nanoparticle

 #15
20250161211
2025-05-22

LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A

 #16
20250152735
2025-05-15

Lipid Nanoparticle Compositions and Methods for mRNA Delivery

 #17
20250144240
2025-05-08

METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE

 #18
20250137012
2025-05-01

COMPOSITIONS AND METHODS OF USING TWO-PROMOTER VECTOR FOR TREATMENT OF LYSOSOMAL STORAGE DISORDERS

 #19
20250134968
2025-05-01

THERAPEUTIC REGIMEN FOR THE TREATMENT OF FABRY USING STABILIZED ALPHA-GALACTOSIDASE

 #20
20250120976
2025-04-17

BIOMARKERS OF METHOTREXATE-INDUCED IMMUNE TOLERANCE

 #21
20250108126
2025-04-03

Lipid Nanoparticle Compositions and Methods for mRNA Delivery

 #22
20250099558
2025-03-27

LYOPHILIZED FORMULATION COMPRISING A FUSION PROTEIN INCLUDING a-GALACTOSIDASE A

 #23
20250099367
2025-03-27

TARGETED DELIVERY OF MODIFIED RNA

 #24
20250066812
2025-02-27

RECOMBINANT AAV FOR THE GENE THERAPY OF FABRY DISEASE

 #25
20250041388
2025-02-06

Human alpha-galactosidase variants

 #26
20250041194
2025-02-06

COMPOSITION COMPRISING GALACTINOL AND USE THEREOF

 #27
20240417427
2024-12-19

Integrated Continuous Manufacturing of Therapeutic Protein Drug Substances

 #28
20240408157
2024-12-12

COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE

 #29
20240408020
2024-12-12

Lyophilized Pharmaceutical Compositions Comprising a Lipid Nanoparticle

 #30
20240398729
2024-12-05

Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders

 #31
20240360431
2024-10-31

ENGINEERED ALPHA-GALACTOSIDASE A (A-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF AND ASSOCIATED METHODS OF TREATING FABRY DISEASE

 #32
20240336949
2024-10-10

DIGITAL MICROBIOLOGY

 #33
20240327475
2024-10-03

ICAM-1 targeted fusion enzymes

 #34
20240301380
2024-09-12

Compositions and Methods for Treating Fabry Disease

 #35
20240279187
2024-08-22

COMPOUNDS, DEVICES, AND USES THEREOF

 #36
20240240195
2024-07-18

COMPOSITIONS AND METHODS FOR INCREASING EXTRACTIBILITY OF SOLIDS FROM COFFEE BEANS

 #37
20240218342
2024-07-04

SITE-SPECIFIC GLYCAN REMODELING OF LYSOSOMAL ENZYMES AND APPLICATIONS THEREOF

 #38
20240209336
2024-06-27

GENETICALLY MODIFIED HUMAN CELL LINES AND USES THEREOF

 #39
20240175054
2024-05-30

COMPOSITION AND METHODS FOR THE TREATMENT OF FABRY DISEASE

 #40
20240115502
2024-04-11

LIPOSOMES AND ITS USE FOR ENZYME DELIVERY

 #41
20240035056
2024-02-01

Method and special complex enzyme for hydrolyzing galactomannan (GM) to prepare small-molecule GM and galactomannan oligosaccharide (GMOS)

 #42
20240025943
2024-01-25

METHOD FOR OBTAINING MATERIAL FROM PLANT CELL SURFACES

 #43
20240018498
2024-01-18

CODON OPTIMIZED GLA GENES AND USES THEREOF

 #44
20240003901
2024-01-04

ASSAYS FOR FABRY DISEASE TREATMENT

 #45
20230416715
2023-12-28

LYSOSOMAL ENZYMES MODIFIED BY CELL BASED GLYCOENGINEERING

 #46
20230405093
2023-12-21

USE OF THERAPEUTIC ENZYME FUSION PROTEIN IN PREVENTION AND TREATMENT OF RENAL DISEASES CAUSED BY OR ACCOMPANIED BY FABRY DISEASE

 #47
20230365955
2023-11-16

COMPOSITIONS AND METHODS FOR TREATMENT OF FABRY DISEASE

 #48
20230365954
2023-11-16

AFFINITY PURIFICATION OF GLYCOSIDE-CLEAVING ENZYMES

 #49
20230340507
2023-10-26

Yeast promotors for protein expression

 #50
20230332112
2023-10-19

Novel In Vitro and In Vivo Enrichment Strategy Targeting Lymphocytes Derived from Vector Transduced HSCS for Therapy of Disorders

 #51
20230330262
2023-10-19

Lipid nanoparticle compositions and methods for mRNA delivery

 #52
20230323371
2023-10-12

POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE

 #53
20230293723
2023-09-21

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

 #54
20230285593
2023-09-14

Lipid nanoparticle compositions and methods for MRNA delivery

 #55
20230285592
2023-09-14

Lipid nanoparticle compositions and methods for MRNA delivery

 #56
20230285329
2023-09-14

Methods and compositions for the treatment of steatosis-associated disorders

 #57
20230285328
2023-09-14

Methods and Compositions for the Treatment of Steatosis-Associated Disorders

 #58
20230279435
2023-09-07

Adeno-associated virus variant capsids and methods of use thereof

 #59
20230190964
2023-06-22

Codon optimized GLA genes and uses thereof

 #60
20230180791
2023-06-15

ANIMAL FEED COMPOSITIONS

 #61
20230158123
2023-05-25

Recombinant Alpha-Galactosidase A For Treatment Of Fabry Disease

 #62
20230074255
2023-03-09

STABILIZED ALPHA-GALACTOSIDASE AND USES THEREOF

 #63
20220380791
2022-12-01

Glycosylated lysosomal proteins, method of production and uses

 #64
20220378939
2022-12-01

Lipid nanoparticle compositions and methods for mRNA delivery

 #65
20220362406
2022-11-17

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

 #66
20220356458
2022-11-10

Human alpha-galactosidase variants

 #67
20220348896
2022-11-03

Improved Alpha-Galactosidase Protein for Enzyme Replacement Therapy (ERT) and Methods of Use

 #68
20220275409
2022-09-01

A GENETICALLY MODIFIED FUNGUS AND METHODS AND USES RELATED THERETO

 #69
20220273819
2022-09-01

METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE

 #70
20220251145
2022-08-11

Adeno-associated virus variant capsids and methods of use thereof

 #71
20220204963
2022-06-30

OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF

 #72
20220204573
2022-06-30

ICAM-1 targeted fusion enzymes

 #73
20220202718
2022-06-30

Cleavable lipids

 #74
20220195484
2022-06-23

Digital microbiology

 #75
20220127591
2022-04-28

Modified recombinant lysosomal alpha-galactosidase A and aspartylglucoaminidase having low mannose-6-phosphate and high sialic acid

 #76
20220112475
2022-04-14

NOVEL ALPHA-GALACTOSIDASE A DERIVATIVES

 #77
20220111072
2022-04-14

Lipid nanoparticle compositions and methods for mRNA delivery

 #78
20220111071
2022-04-14

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

 #79
20220111070
2022-04-14

Lipid nanoparticle compositions and methods for MRNA delivery

 #80
20220105201
2022-04-07

Lipid nanoparticle compositions and methods for mRNA delivery

 #81
20220096607
2022-03-31

SUBCUTANEOUS THERAPEUTIC ENZYME FORMULATIONS, USES, AND METHODS FOR GENERATING THEREOF

 #82
20220090129
2022-03-24

RECOMBINANT ADENO-ASSOCIATED VIRAL VECTOR FOR GENE DELIVERY

 #83
20220064617
2022-03-03

Recombinant Glycoproteins and Uses Thereof

 #84
20220054710
2022-02-24

Decellularization of Plant Cell Culture Materials for Tissue Engineering and Drug Delivery

 #85
20220054602
2022-02-24

mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES

 #86
20220040330
2022-02-10

Lipid nanoparticle compositions and methods for mRNA delivery

 #87
20220040126
2022-02-10

Methods and compositions for the treatment of cytoplasmic glycogen storage disorders

 #88
20220023443
2022-01-27

Disulfide bond stabilized polypeptide compositions and methods of use

 #89
20210380643
2021-12-09

Adeno-associated virus variant capsids and methods of use thereof

 #90
20210332341
2021-10-28

Codon optimized GLA genes and uses thereof

 #91
20210322472
2021-10-21

Use of lentivector-transduced T-Rapa cells for amelioration of lysosomal storage disorders

 #92
20210300755
2021-09-30

Lipid nanoparticle compositions and methods for mRNA delivery

 #93
20210292726
2021-09-23

Polypeptides having alpha-galactosidase activity and polynucleotides encoding same

 #94
20210269787
2021-09-02

HUMAN ALPHA-GALACTOSIDASE VARIANTS

 #95
20210261557
2021-08-26

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

 #96
20210251922
2021-08-19

Methods and compositions for the treatment of steatosis-associated disorders

 #97
20210244804
2021-08-12

Human alpha-galactosidase variants

 #98
20210222185
2021-07-22

COMPOSITIONS AND METHODS FOR INCREASING EXTRACTABILITY OF SOLIDS FROM COFFEE BEANS

 #99
20210147495
2021-05-20

ICAM-1 targeted fusion enzymes

 #100
20210060177
2021-03-04

Lipid nanoparticle compositions and methods for mRNA delivery

 #101
20210040465
2021-02-11

Affinity purification of glycosidase-cleaving enzymes

 #102
20210032643
2021-02-04

Yeast promotors for protein expression

 #103
20210017500
2021-01-21

ANIMAL CELL STRAIN AND METHOD FOR USE IN PRODUCING GLYCOPROTEIN, GLYCOPROTEIN AND USE THEREOF

 #104
20210009984
2021-01-14

THERAPEUTIC ENZYME FUSION PROTEIN HAVING A NOVEL STRUCTURE AND USE THEREOF

 #105
20210008074
2021-01-14

Biomarkers of methotrexate-induced immune tolerance

 #106
20200405826
2020-12-31

Human alpha-galactosidase variants

 #107
20200399669
2020-12-24

Polypeptides Having Alpha-Galactosidase Activity and Polynucleotides Encoding Same

 #108
20200399668
2020-12-24

Polypeptides Having Alpha-Galactosidase Activity and Polynucleotides Encoding Same

 #109
20200369718
2020-11-26

Sterile chromatography and manufacturing processes

 #110
20200360490
2020-11-19

Human alpha-galactosidase variants

 #111
20200360489
2020-11-19

Human alpha-galactosidase variants

 #112
20200338214
2020-10-29

Lipid nanoparticle compositions and methods for mRNA delivery

 #113
20200317726
2020-10-08

Integrated continuous manufacturing of therapeutic protein drug substances

 #114
20200296976
2020-09-24

Enzyme exhibiting fructan hydrolase activity

 #115
20200270313
2020-08-27

COMPOSITIONS AND METHODS FOR SUPPRESSION OF INHIBITOR FORMATION AGAINST COAGULATION FACTORS IN HEMOPHILIA PATIENTS

 #116
20200239911
2020-07-30

METHODS AND COMPOSITIONS FOR THE TREATMENT OF FABRY DISEASE

 #117
20200237671
2020-07-30

Cleavable lipids

 #118
20200231989
2020-07-23

Methods and compositions for the treatment of lysosomal storage diseases

 #119
20200199563
2020-06-25

Human alpha-galactosidase variants

 #120
20200181582
2020-06-11

and enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders

 #121
20200155654
2020-05-21

Therapeutic regimen for the treatment of Fabry using stabilized alpha-galactosidase

 #122
20200149052
2020-05-14

Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease

 #123
20200147241
2020-05-14

Disulfide bond stabilized polypeptide compositions and methods of use

 #124
20200131493
2020-04-30

Elution of biomolecules from multi-modal resins using MES and MOPS as mobile phase modifiers

 #125
20200115698
2020-04-16

PHARMACEUTICAL COMBINATION FOR TREATMENT OF FABRY DISEASE AND USE THEREOF

 #126
20200086147
2020-03-19

COMPOSITION OF DIGESTIVE ENZYMES AND APPETITE SUPPRESSANTS

 #127
20200085973
2020-03-19

LIPID NANOPARTICLE COMPOSITIONS AND METHODS FOR MRNA DELIVERY

 #128
20200061245
2020-02-27

Decellularization of plant cell culture materials for tissue engineering and drug delivery

 #129
20200048266
2020-02-13

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

 #130
20200039943
2020-02-06

Compounds, devices, and uses thereof

 #131
20200010825
2020-01-09

Oligosaccharides comprising an aminooxy group and conjugates thereof

 #132
20190358302
2019-11-28

Recombinant α-galactosidase A for treatment of Fabry disease

 #133
20190321489
2019-10-24

Lipid nanoparticle compositions and methods for mRNA delivery

 #134
20190314284
2019-10-17

Cleavable lipids

 #135
20190289880
2019-09-26

Animal feed additives

 #136
20190256832
2019-08-22

Stabilized alpha-galactosidase and uses thereof

 #137
20190255156
2019-08-22

Treatment of α-galactosidase a deficiency

 #138
20190225579
2019-07-25

Treatment of Fabry disease

 #139
20190224282
2019-07-25

Targeted Therapeutic Proteins

 #140
20190209664
2019-07-11

Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof

 #141
20190203239
2019-07-04

Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from and related organisms, methods

 #142
20190194265
2019-06-27

Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients

 #143
20190192689
2019-06-27

Lipid nanoparticle compositions and methods for mRNA delivery

 #144
20190175761
2019-06-13

Lipid nanoparticle compositions and methods for mRNA delivery

 #145
20190174773
2019-06-13

Enzyme exhibiting fructan hydrolase activity

 #146
20190144902
2019-05-16

Polypeptides having alpha-galactosidase activity and polynucleotides encoding same

 #147
20190106691
2019-04-11

Glycosylation independent proteins

 #148
20190091335
2019-03-28

ANTIBODY FORMULATIONS CONTAINING AMINO ACIDS

 #149
20190083639
2019-03-21

Scavenger receptor uptake for Fabry disease enzyme replacement therapy

 #150
20190055539
2019-02-21

Method for controlling enzyme productivity of microorganisms

 #151
20190054154
2019-02-21

Targeting of glycoprotein therapeutics

 #152
20190048378
2019-02-14

HEMICELLULASE ENRICHED COMPOSITIONS FOR ENHANCING HYDROLYSIS OF BIOMASS

 #153
20190046657
2019-02-14

Conjugate of therapeutic enzymes

 #154
20190046471
2019-02-14

Methods and compositions for the treatment of steatosis-associated disorders

 #155
20190032105
2019-01-31

Digital microbiology

 #156
20190002929
2019-01-03

Method for the simultaneous production of ethanol and a fermented, solid product

 #157
20190002890
2019-01-03

Polynucleotides encoding alpha-galactosidase A for the treatment of Fabry disease

 #158
20190000933
2019-01-03

Polynucleotides encoding α-galactosidase A for the treatment of Fabry disease

 #159
20190000932
2019-01-03

POLYNUCLEOTIDES ENCODING ALPHA-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE

 #160
20180362947
2018-12-20

Methods of purifying recombinant alpha-Galactosidase A

 #161
20180354986
2018-12-13

STERILE CHROMATOGRAPHY AND MANUFACTURING PROCESSES

 #162
20180327758
2018-11-15

RECOMBINANT MICROALGAE INCLUDING KETO-ACYL ACP SYNTHASE

 #163
20180265910
2018-09-20

Cleavage of Fucose in N-Glycans

 #164
20180236048
2018-08-23

Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof

 #165
20180236047
2018-08-23

MRNA for use in treatment of human genetic diseases

 #166
20180201964
2018-07-19

Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from and related organisms, methods

 #167
20180185495
2018-07-05

THERAPEUTIC COMPOSITIONS OF ALPHA-L-IDURONIDASE, IDURONATE-2-SULFATASE, AND ALPHA-GALACTOSIDASE A AND METHODS OF USE THEREOF

 #168
20180169020
2018-06-21

Cleavable lipids

 #169
20180148703
2018-05-31

Stabilized α-galactosidase and uses thereof

 #170
20180117181
2018-05-03

Methods and compositions for the treatment of Fabry disease

 #171
20180117130
2018-05-03

Enzyme formulation for reducing histamine intolerance

 #172
20180055911
2018-03-01

Targeted therapeutic proteins

 #173
20180016648
2018-01-18

Glycosylated lysosomal proteins, method of production and uses

 #174
20180016564
2018-01-18

Method for production of recombinant human alpha-galactosidase A from material containing contaminant host cell proteins by chromatography

 #175
20180008543
2018-01-11

Cleavable Lipids

 #176
20170360901
2017-12-21

α-galactosidase A and 1-deoxygalactonojirimycin co-formulation

 #177
20170360900
2017-12-21

HUMAN ALPHA-GALACTOSIDASE VARIANTS

 #178
20170274056
2017-09-28

Enzyme formulation for reducing histamine intolerance

 #179
20170239371
2017-08-24

Lipid nanoparticle compositions and methods for MRNA delivery

 #180
20170233767
2017-08-17

Method for the simultaneous production of ethanol and a fermented, solid product

 #181
20170226493
2017-08-10

Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose

 #182
20170218012
2017-08-03

Integrated continuous manufacturing of therapeutic protein drug substances

 #183
20170216411
2017-08-03

Treatment of alpha-galactosidase a deficiency

 #184
20170209548
2017-07-27

Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease

 #185
20170130205
2017-05-11

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELLS

 #186
20170128547
2017-05-11

Use of Hydrolytic and Oxidative Enzymes to Dissolve Biofilm in Ears

 #187
20170087227
2017-03-30

ORALLY ADMINISTERED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME, COMPRISING AN INTESTINAL MOTILITY MODIFIER, AN AGENT THAT PREVENTS GAS RETENTION, AND DIGESTIVE ENZYMES, AND PREPARATION METHOD THEREOF

 #188
20170051267
2017-02-23

NOVEL ALPHA-GALACTOSIDASE A DERIVATIVES

 #189
20170042979
2017-02-16

TARGETING OF GLYCOPROTEIN THERAPEUTICS

 #190
20170000830
2017-01-05

Compositions for Relieving the Symptoms of Gluten Sensitivity and Methods of Use Thereof

 #191
20160303289
2016-10-20

Method for preparing biological tissue

 #192
20160303206
2016-10-20

PHARMACEUTICAL OR NUTRITIONAL COMPOSITIONS CONTAINING GALACTOSIDASE, AND THEIR USE

 #193
20160299119
2016-10-13

Analytical method for determining the concentration of oxidized nanofibrillar cellulose in a sample

 #194
20160298158
2016-10-13

Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from and related organisms, methods

 #195
20160289277
2016-10-06

Compositions and methods for suppression of inhibitor formation against coagulation factors in hemophilia patients

 #196
20160271253
2016-09-22

Protein Formulations Containing Amino Acids

 #197
20160264953
2016-09-15

Recombinant glycoproteins and uses thereof

 #198
20160207933
2016-07-21

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

 #199
20160186191
2016-06-30

Tailored oils produced from recombinant heterotrophic microorganisms

 #200
20160184409
2016-06-30

Treatment of α-galactosidase A deficiency

 #201
20160183561
2016-06-30

Polypeptides having a-L-Galactosidase Activity and Polynucleotides Encoding Same

 #202
20160152680
2016-06-02

Targeted therapeutic proteins

 #203
20160114012
2016-04-28

Enzyme formulation for use as food supplement

 #204
20160101160
2016-04-14

mRNA for use in treatment of human genetic diseases

 #205
20160100599
2016-04-14

Use of glycosidase in preparation of a milk product

 #206
20160060656
2016-03-03

Method of treating mucopolysaccharidosis type I or II

 #207
20160053247
2016-02-25

Stabilized alpha-galactosidase and uses thereof

 #208
20160040146
2016-02-11

Purification of recombinant alpha galactosidase A

 #209
20160024538
2016-01-28

Recombinant microalgae including keto-acyl ACP synthase

 #210
20160024511
2016-01-28

Yeast promoters for protein expression

 #211
20150320844
2015-11-12

Targeting of glycoprotein therapeutics

 #212
20150306187
2015-10-29

SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A

 #213
20150275250
2015-10-01

Thermophilic and thermoacidophilic biopolymer degrading genes and enzymes from and related organisms, methods

 #214
20150275195
2015-10-01

ELUTION OF BIOMOLECULES FROM MULTI-MODAL RESINS USING MES AND MOPS AS MOBILE PHASE MODIFIERS

 #215
20150259656
2015-09-17

MODIFIED FUNGAL CELL

 #216
20150203532
2015-07-23

STERILE CHROMATOGRAPHY AND MANUFACTURING PROCESSES

 #217
20150203529
2015-07-23

Sterile chromatography and manufacturing processes

 #218
20150190530
2015-07-09

Functionalized liposomes useful for the delivery of bioactive compounds

 #219
20150183821
2015-07-02

Integrated continuous manufacturing of therapeutic protein drug substances

 #220
20150174214
2015-06-25

α-galactosidase A and 1-deoxygalactonojirimycin co-formulation

 #221
20150050262
2015-02-19

Oligosaccharides comprising an aminooxy group and conjugates thereof

 #222
20150017149
2015-01-15

Method of treating GERD with alpha and beta galactosidases

 #223
20150004217
2015-01-01

mRNA for use in treatment of human genetic diseases

 #224
20140323356
2014-10-30

Glycosidase enzymes

 #225
20140288160
2014-09-25

Cleavable lipids

 #226
20140271577
2014-09-18

Plant cell culture expressing human lysosomal proteins and uses thereof

 #227
20140255994
2014-09-11

Integrated continuous manufacturing of therapeutic protein drug substances

 #228
20140171493
2014-06-19

Highly functional enzyme having alpha-galactosidase activity

 #229
20140171491
2014-06-19

Intranasal delivery of AAV encoding therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

 #230
20140050666
2014-02-20

Scavenger receptor uptake for fabry disease enzyme replacement therapy

 #231
20140044694
2014-02-13

Pharmaceutical composition for treating lysosomal storage disease

 #232
20130316406
2013-11-28

Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from and related organisms, methods

 #233
20130251848
2013-09-26

Use of glycosidase in preparation of a milk product

 #234
20130064805
2013-03-14

Highly functional enzyme having α-galactosidase activity

 #235
20130059009
2013-03-07

COMPOSITIONS AND METHODS FOR PRODUCING ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS WITH SYNTHETIC NANOCARRIERS

 #236
20130058978
2013-03-07

INDUCED TOLEROGENIC DENDRITIC CELLS FOR INDUCING REGULATORY B CELLS

 #237
20130058977
2013-03-07

COMPOSITIONS AND METHODS RELATED TO INDUCED TOLEROGENIC DENDRITIC CELLS EXTERNALLY LOADED WITH MHC CLASS I-RESTRICTED EPITOPES

 #238
20130058976
2013-03-07

ALLERGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS FOR ALLERGY THERAPY

 #239
20130058975
2013-03-07

ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE ANTIBODY RESPONSES

 #240
20130058974
2013-03-07

ANTIGEN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE CYTOTOXIC T LYMPHOCYTE RESPONSES

 #241
20130058970
2013-03-07

INDUCED TOLEROGENIC DENDRITIC CELLS TO REDUCE SYSTEMIC INFLAMMATORY CYTOKINES

 #242
20130058963
2013-03-07

INDUCED TOLEROGENIC DENDRITIC CELLS FOR GENERATING CD8+ REGULATORY T CELLS

 #243
20130058902
2013-03-07

DENDRITIC CELL SUBSETS FOR GENERATING INDUCED TOLEROGENIC DENDRITIC CELLS AND RELATED COMPOSITIONS AND METHODS

 #244
20130058901
2013-03-07

TRANSPLANTABLE GRAFT-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE

 #245
20130058894
2013-03-07

THERAPEUTIC PROTEIN-SPECIFIC INDUCED TOLEROGENIC DENDRITIC CELLS AND METHODS OF USE

 #246
20130004646
2013-01-03

Compositions Comprising Tailored Oils

 #247
20120328592
2012-12-27

Stabilized alpha-galactosidase and uses thereof

 #248
20120324784
2012-12-27

Tailored oils produced from recombinant heterotrophic microorganisms

 #249
20120288489
2012-11-15

Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases

 #250
20120282231
2012-11-08

Human lysosomal proteins from plant cell culture

 #251
20120276078
2012-11-01

Glycosidase enzymes

 #252
20120202273
2012-08-09

comprising an α-galactosidase for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells

 #253
20120142756
2012-06-07

mRNA for use in treatment of human genetic diseases

 #254
20120141507
2012-06-07

Targeting of glycoprotein therapeutics

 #255
20120141453
2012-06-07

Glycosidase Enzymes

 #256
20120141452
2012-06-07

Targeted therapeutic proteins

 #257
20120040474
2012-02-16

Glycan-specific analytical tools

 #258
20110294174
2011-12-01

Tailored oils produced from recombinant heterotrophic microorganisms

 #259
20110293785
2011-12-01

FOOD COMPOSITIONS COMPRISING TAILORED OILS

 #260
20110280856
2011-11-17

TREATMENT OF ALPHA-GALACTOSIDASE A DEFICIENCY

 #261
20110250181
2011-10-13

Human lysosomal proteins from plant cell culture

 #262
20110182868
2011-07-28

Human lysosomal proteins from plant cell culture

 #263
20110171198
2011-07-14

Highly functional enzyme having α-galactosidase activity

 #264
20110154519
2011-06-23

phytase

 #265
20110136175
2011-06-09

Thermophilic and thermoacidophilic biopolymer-degrading genes and enzymes from alicyclobacillus acidocaldarius and related organisms, methods

 #266
20110086408
2011-04-14

Hemicellulase Enriched Compositions for Enhancing Hydrolysis of Biomass

 #267
20110059487
2011-03-10

ENGINEERED MICROORGANISMS AND METHODS OF USE

 #268
20110045569
2011-02-24

α-galactosidases for removing immunodominant α-galactose monosaccharides from blood group B or AB reactive cells

 #269
20110014170
2011-01-20

Methods of preparing tissues for xenotransplantation using α-galactosidases

 #270
20110002908
2011-01-06

Treatment of α-galactosidase A deficiency

 #271
20100311845
2010-12-09

Glycosidase enzymes

 #272
20100291060
2010-11-18

SUBCUTANEOUS ADMINISTRATION OF ALPHA-GALACTOSIDASE A

 #273
20100285539
2010-11-11

Process for manufacturing tagatose using soy oligosaccharide

 #274
20100273235
2010-10-28

Stabilized aqueous alpha-galactosidase composition and methods relating thereto

 #275
20100209411
2010-08-19

USE OF HYDROLYTIC AND OXIDATIVE ENZYMES TO DISSOLVE BIOFILM IN EARS

 #276
20100196345
2010-08-05

PRODUCTION OF HIGH MANNOSE PROTEINS IN PLANT CULTURE

 #277
20100166728
2010-07-01

Highly functional enzyme having α-galactosidase activity

 #278
20100112134
2010-05-06

Bioactive raw vegetables

 #279
20100068183
2010-03-18

Methods of treating lysosomal storage related diseases by gene therapy

 #280
20100047225
2010-02-25

Oligosaccharides comprising an aminooxy group and conjugates thereof

 #281
20090220474
2009-09-03

Method of preparing non-human tissues for xenotransplantation using α-galactosidase

 #282
20090208477
2009-08-20

Production of high mannose proteins in plant culture and therapeutic uses thereof

 #283
20090203575
2009-08-13

TARGETED THERAPEUTIC PROTEINS

 #284
20090142326
2009-06-04

Glycosidase enzymes

 #285
20090029467
2009-01-29

Method for targeting lysosomal enzymes

 #286
20090004327
2009-01-01

Enzyme product for ruminants

 #287
20080279985
2008-11-13

ENZYMES HAVING GLYCOSIDASE ACTIVITY AND METHODS OF USE THEREOF

 #288
20080263688
2008-10-23

Hafnia phytase

 #289
20080226658
2008-09-18

Targeting of glycoprotein therapeutics

 #290
20080038232
2008-02-14

Human lysosomal proteins from plant cell culture

 #291
20070269562
2007-11-22

Bioactive raw vegetables

 #292
20070269555
2007-11-22

Enzyme Formulations

 #293
20070238693
2007-10-11

Genetic modification of the lung as a portal for gene delivery

 #294
20070036883
2007-02-15

Plant-derived alkaline alpha-galactosidase

 #295
20060228348
2006-10-12

Targeting of glycoprotein therapeutics

 #296
20060216401
2006-09-28

Process for producing a carbohydrate composition

 #297
20060193843
2006-08-31

Thermostable enzyme compositions

 #298
20060177433
2006-08-10

Treatment of α-galactosidase A deficiency

 #299
20060084163
2006-04-20

Plant-derived alkaline alpha-galactosidase

 #300
20060057114
2006-03-16

Methods of treating lysosomal storage related diseases by gene therapy